1) Strategic Focus and Leadership Changes
- Novo Nordisk achieved 10% sales growth and 6% operating profit growth in 2025, emphasizing a strategic focus on obesity and diabetes care.
- The company has doubled its sales and operating profit since 2019, with obesity care sales soaring from DKK 6 billion to DKK 82 billion.
- Key leadership changes were announced, with Dave Moore and Ludovic Helfgott departing. Jamey Millar and Hong Chow will join the executive team, bringing extensive industry experience.
- The company aims to expand access to its therapies, having reached an additional 16 million patients in obesity and diabetes care.

2) Financial and Segment Results
- Total sales increased by 10%, with U.S. operations growing by 8% and International Operations by 14%.
- Obesity care sales surged 31%, driven by the success of Wegovy, which launched in 35 new countries and generated DKK 28 billion in sales, a 134% increase.
- Rare Disease sales rose by 9%, primarily from the uptake of Sogroya.
- Gross margin decreased to 81% from 84.7% in 2024, impacted by restructuring costs and amortization related to acquisitions.

3) Operational Plans and Product Pipeline
- The FDA approved the Wegovy pill, the first oral GLP-1 for obesity, which launched in January 2026 with promising early uptake.
- Upcoming trials include CagriSema and zenagamtide, with significant weight loss efficacy demonstrated in Phase III trials.
- The company plans to expand its obesity and diabetes markets through new online channels and partnerships, alongside the rollout of new products.

4) Guidance and Outlook
- For 2026, Novo Nordisk expects adjusted sales growth to decline by 5% to 13% at constant exchange rates, reflecting pricing headwinds and competitive pressures.
- The guidance incorporates anticipated challenges from the 340B Drug Pricing Program and increased competition, particularly in the U.S.
- Despite headwinds, the company remains optimistic about expanding patient reach and volume growth in obesity and diabetes care.

5) Missing Information and Final Remarks
- The transcript lacks specific figures on the expected impact of generic competition in International Operations, particularly in Canada.
- Bottom line: Novo Nordisk is positioned for continued growth in obesity and diabetes care despite anticipated pricing pressures in 2026, supported by a robust pipeline and strategic leadership changes. The focus remains on expanding patient access and maintaining market leadership in GLP-1 therapies.